Document is current
Any future updates will be listed below
-
Authors
Gu, Yanyan
Barwick, Benjamin G. https://orcid.org/0000-0001-9810-3566
Shanmugam, Mala
Hofmeister, Craig C.
Kaufman, Jonathan https://orcid.org/0000-0002-5687-6429
Nooka, Ajay https://orcid.org/0000-0003-4165-6869
Gupta, Vikas
Dhodapkar, Madhav https://orcid.org/0000-0002-8249-5988
Boise, Lawrence H. https://orcid.org/0000-0001-9436-8815
Lonial, Sagar https://orcid.org/0000-0002-8322-9323
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
Celgene
- License Information
-
More Information
Article History
Received: 26 June 2020
Revised: 14 October 2020
Accepted: 28 October 2020
First Online: 14 December 2020
Conflict of interest
: S.L. is a consultant for Takeda, Celgene, Amgen, Novartis, and BMS. L.H.B. is a consultant and has received research funding from AstraZeneca and served on an advisory board for Genentech. C.C.H. received research grants from Takeda, Oncolytics Biotech, research and personal grants from Janssen, BMS, Sanofi, Nektar, and Karyopharm, and personal grants from Imbrium and Oncopeptides, all outside the submitted work. The remaining authors declare no competing financial interests.
